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Background. Deﬁcits in memory and executive performance are well-established features of bipolar disorder and
schizophrenia. By contrast, data on cognitive impairment in schizoaﬀective disorder are scarce and the ﬁndings are
conﬂicting.
Method. We used the Wechsler Memory Scale (WMS-III) and the Behavioural Assessment of the Dysexecutive
Syndrome (BADS) to test memory and executive function in 45 schizophrenic patients, 26 schizomanic patients and
51 manic bipolar patients in comparison to 65 healthy controls. The patients were tested when acutely ill.
Results. All three patient groups performed signiﬁcantly more poorly than the controls on global measures of
memory and executive functioning, but there were no diﬀerences among the patient groups. There were few
diﬀerences in memory and executive function subtest scores within the patient groups. There were no diﬀerences in
any test scores between manic patients with and without psychotic symptoms.
Conclusions. Schizophrenic, schizomanic and manic patients show a broadly similar degree of executive and
memory deﬁcits in the acute phase of illness. Our results do not support a categorical diﬀerentiation across diﬀerent
psychotic categories with regard to neuropsychological deﬁcits.
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Introduction
Schizoaﬀective disorder is a boundary condition
that challenges the Kraepelinian dichotomy between
schizophrenia and major aﬀective disorder, and
perhaps even the whole categorical classiﬁcation of
psychotic disorders. Arguments have been made that
it is an independent entity (Procci, 1976), a subtype of
schizophrenia (Lehman, 1975), a variant of bipolar
disorder (Clayton et al. 1968) or the midpoint on a con-
tinuum of psychosis (Crow, 1986). These arguments
have relied on two sources of evidence, follow-up
studies and family history studies, neither of which
have proved decisive. Patients diagnosed as schizo-
aﬀective tend to have an outcome intermediate be-
tween schizophrenia and bipolar disorder (for a re-
view, see McKenna, 2007), and they show elevated
rates of both schizophrenia and bipolar disorder in
their ﬁrst-degree relatives (for a review, see Coryell,
1986).
A further potential source of evidence is neuro-
psychological studies. In a review of the literature,
Buchanan et al. (2005) concluded that schizophrenia
and schizoaﬀective disorder shared a similar pattern
of cognitive deﬁcits which was distinct from that seen
in major depression and bipolar disorder. However,
this conclusion was based on only two studies, one
comparing schizoaﬀective patients and schizophrenic
patients (Miller et al. 1996) and the other comparing
schizoaﬀective patients with groups with schizo-
phrenia and non-psychotic mood disorder (Evans et al.
1999). More recently, Bora et al. (2009) have published
a meta-analysis that compared neuropsychological
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test performance in patients with schizophrenia to
those with schizoaﬀective psychosis and psychotic
forms of aﬀective disorder. Pooled diﬀerences on six
measures of memory, executive function and mental
speed were all in the direction of better performance in
the schizoaﬀective patients, with the eﬀect sizes being
signiﬁcant in ﬁve out of six cases (range 0.08 to 0.32).
However, they also found that the pooled diﬀerences
between schizophrenia and psychotic aﬀective dis-
order were of the same magnitude in these domains.
Studies comparing schizoaﬀective disorder with
bipolar disorder are fewer in number and have had
conﬂicting ﬁndings. Evans et al. (1999) found that 29
schizoaﬀective and 154 schizophrenic patients were
more impaired than 27 patients with non-psychotic
mood disorder on a composite neuropsychological
score, but there were no signiﬁcant diﬀerences be-
tween the schizophrenic and schizoaﬀective groups.
Torrent et al. (2007) found that 34 schizoaﬀective
patients showed signiﬁcantly more impairment than
41 patients with bipolar disorder on tests of short- and
long-term verbal memory, and on two out of four
executive measures. However, Studentkowski et al.
(2010) had more mixed ﬁndings : 28 schizoaﬀective
patients showed more impairment than 32 bipolar
patients on tests of attention, psychomotor speed and
memory, but there were no signiﬁcant diﬀerences on
measures of cognitive ﬂexibility and emotional mem-
ory. Finally, Szoke et al. (2008) found no signiﬁcant
diﬀerences on two executive tests, the Wisconsin Card
Sorting Test (WCST) and the Trail Making Test (TMT),
in 26 schizoaﬀective patients compared to 52 and 40
patients with psychotic and non-psychotic forms of
bipolar disorder respectively.
One possible reason for the divergent ﬁndings in
this latter group of studies might be the presence or
absence of psychotic symptoms in the bipolar com-
parison group. For example, Simonsen et al. (2011)
found no diﬀerences between 27 schizoaﬀective and
75 bipolar patients with a history of psychotic symp-
toms on a battery of seven tests covering memory,
processing speed and executive function ; however,
there were signiﬁcant diﬀerences compared to 61
patients with non-psychotic forms of bipolar disorder
on four of these tests. Glahn et al. (2006) found that
15 schizoaﬀective patients did not diﬀer from 11 psy-
chotic bipolar patients on three tests of short-term
and working memory. Greater diﬀerences from non-
psychotic bipolar patients were evident on all the tests,
but the authors did not state whether these reached
signiﬁcance.
A further issue that might aﬀect cognitive perform-
ance in groups of psychotic patients is the degree to
which they are symptomatic at the time of testing. This
applies particularly to aﬀective disorder, where, in the
words of Murray et al. (2004) : ‘Many studies have
noted cognitive deﬁcits in acutely psychotic patients
with aﬀective disorder, but the crucial question is
whether, in contrast to schizophrenia, these deﬁcits
completely resolve with remission. ’ Even allowing for
the fact that a proportion of bipolar patients will con-
tinue to show cognitive impairment when they are
euthymic (e.g. Robinson et al. 2006), it is still possible
that studies comparing schizophrenia, schizoaﬀective
disorder and bipolar disorder will have diﬀerent
ﬁndings depending on whether the bipolar (and
perhaps also the schizoaﬀective) patients are exam-
ined when they were acutely ill or recovered.
The aim of this study was to further examine the
question of whether there is a pattern of decreasing
cognitive impairment from schizophrenia to schi-
zoaﬀective disorder to bipolar disorder. We also ad-
dressed the two problems identiﬁed above, testing all
patients when they were in an active phase of illness,
and carrying out a comparison between manic
patients with and without psychotic symptoms.
Method
Subjects
The patient sample (n=122) consisted of three diﬀer-
ent diagnostic groups (schizomanic patients, n=26;
manic patients, n=51 ; and schizophrenic patients,
n=45) recruited from three Spanish psychiatric
hospitals (Hospital Benito Menni, Sant Boi de
Llobregat ; the psychiatric ward of Hospital General
de Granollers ; and Hospital Clı´nic in Barcelona),
where they had been admitted for a relapse of
illness. Patients were excluded if : (a) they were aged
<18 years or >65 years, (b) had a history of brain
trauma or neurological disease, and (c) had shown
alcohol/substance abuse within 12 months prior to
participation. All patients were also required to have
an IQ in the normal range : Wechsler Adult Intelli-
gence Scale III (WAIS-III) scoreo70.
All patients were diagnosed using DSM-IV criteria.
This was based on an interview with a psychiatrist,
with a second psychiatrist being involved in cases of
doubt. The schizoaﬀective patients also met the more
rigorous Research Diagnostic Criteria (RDC) for this
disorder (Spitzer et al. 1978).
All patients were taking medication. In the bipolar
patients, 43/51 were on one or more mood stabilizers
and 46/51 were taking typical and/or atypical anti-
psychotics. In the schizoaﬀective group, 19/26
patients were taking mood stabilizers and all of them
were on typical and/or atypical antipsychotic drugs.
Three of the 45 schizophrenic patients were taking
a mood stabilizer and all but one were receiving
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antipsychotic medication. There was no diﬀerence
between the groups with regard to antipsychotic dose,
calculated in chlorpromazine equivalents (bipolar
mean: 653.04¡491.26 ; schizoaﬀective mean: 776.30¡
529.50 ; schizophrenia mean: 793.90¡510.28 ; F2,119=
1.06, p=0.35).
All patients were tested when acutely ill, as deﬁned
as a score of >18 on the Young Mania Rating Scale
(YMRS; Young et al. 1978) in the bipolar manic and
schizomanic patients. Psychotic symptoms were re-
quired to be present in the schizophrenic and schizo-
manic patients, deﬁned on the basis of the following
Positive and Negative Symptom Scale (PANSS; Kay
et al. 1967) items: P1o4, P3o4, P5o5, P6o6 or PG9
o5. Symptoms in all patients were rated on the day of
the neuropsychological assessment.
The controls consisted of 65 Spanish Caucasian
healthy individuals. They were recruited to be age-
and sex-matched to the patients and met the same
exclusion criteria. All controls were recruited from
non-medical staﬀ working in the hospital, their re-
latives and acquaintances, plus independent sources
in the community. They were questioned and ex-
cluded if they reported a history of mental illness and/
or treatment with psychotropic medication.
All participants gave written informed consent and
the study was approved by the hospital research ethics
committee.
Cognitive and neuropsychological assessment
Neuropsychological assessments were carried out
by three psychologists who had no knowledge of
the patients’ diagnoses. Pre-morbid IQ was esti-
mated using the Word Accentuation Test (Test
de Acentuacio´n de Palabras, TAP; Del Ser et al. 1997 ;
Gomar et al. 2011). This is analogous to the English
National Adult Reading Test (NART; Nelson &
Willison, 1991) and requires pronunciation of low-
frequency Spanish words whose accents have been
removed. Current IQ was measured using four sub-
tests of the Spanish version of the WAIS-III :
Vocabulary, Similarities, Matrix Reasoning, and Block
Design. Raw scores were converted into scaled scores
for the relevant age group, and then pro-rated to cal-
culate full-scale IQ.
Memory was assessed using four subtests of the
Spanish version of the Wechsler Memory Scale-III
(WMS-III ; Wechsler, 1997 ; Peren˜a et al. 2004) : verbal
long-term memory (Logical Memory I), visual
memory (Faces I), short-term memory (Digit Span)
and working memory (Letter–Number Sequencing).
Raw scores on these tests are converted into age-
related scaled scores. The scaled scores can then be
arithmetically summed.
Executive function was tested using the Behav-
ioural Assessment of the Dysexecutive Syndrome
(BADS; Wilson et al. 1996 ; Vargas et al. 2009). This is a
wide-ranging battery of executive tests that has been
standardized on groups of normal subjects and
patients with head injury. It has also been adapted for
use in Spanish populations (Vargas et al. 2009). It con-
sists of six subtests. Rule Shift Cards examines set
shifting ability. The Action Programme Test requires
the subject to devise a strategy to remove a cork from a
container, using simple tools such as a stick and water.
In the Key Search Test, the subject has to devise an
eﬃcient plan to search a ﬁeld for a lost object. The
Temporal Judgement Test is a variant of the Cognitive
Estimates Test of Shallice & Evans (1978) ; the subject
has to respond to questions they are unlikely to know
the exact answer to, such as, for example, how long it
takes to clean a window, or how long a dog lives. The
Zoo Map Test requires strategic planning of a route
in a diagram of a zoo, while following certain rules.
Finally, the Modiﬁed Six Elements Test is a task re-
quiring multi-tasking in which the subject has to carry
out various elements of six diﬀerent activities accord-
ing to a set of rules. Performance on the individual tests
can be combined to give an overall ‘proﬁle ’ score that
can also be adjusted for age (the standardized score).
Statistical analyses
Analyses of variance (ANOVAs) were carried out to
compare overall WMS and BADS scores and WMS
subtests among the patient and control groups. For the
BADS subtests, non-parametric Kruskal–Wallis tests
were used because scores were not normally dis-
tributed. Post-hoc tests with Bonferroni correction were
applied when signiﬁcant main eﬀects were found. In a
subanalysis we divided the bipolar sample into a
group of manic patients with or without psychotic
symptoms. The presence of psychotic symptoms was
deﬁned based on PANSS scores as described above.
The impact of demographic and clinical variables
on neuropsychological performance was investigated
through regression analyses modelling a backward
stepwise method.
Results
Sample characteristics
The patient groups and healthy controls did not diﬀer
in age, sex or estimated pre-morbid IQ. However,
the healthy controls had a signiﬁcantly higher mean
current IQ than the other groups (see Table 1). There
was no diﬀerence in duration of illness among the
patient groups (F2,112=2.18, p=0.118), although this
was numerically shorter in the bipolar patients.
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Regarding psychopathological status, the bipolar
and schizoaﬀective patients scored similarly on the
YMRS. Other ﬁndings were in the expected directions :
the schizoaﬀective patients showed signiﬁcantly
higher scores on PANSS positive (PANSS-P) symp-
toms than the bipolar patients and schizophrenic
patients whereas the schizophrenic patients showed
higher scores on PANSS negative (PANSS-N) symp-
toms and PANSS general psychopathology (PANSS-
GP) than the bipolar (and the schizoaﬀective) patients.
There was no diﬀerence in overall functional impair-
ment among the patient groups, as measured by
Global Assessment of Functioning (GAF) scores over
the past month (Table 1).
Memory
The control group performed signiﬁcantly better
than the schizophrenic, schizoaﬀective and bipolar
patients on WMS composite score but there were no
signiﬁcant diﬀerences among the three patient groups
(Table 2 and Fig. 1).
The signiﬁcant diﬀerences between controls and
patients on the WMS composite score remained sig-
niﬁcant when current (i.e. WAIS-III) IQ, which was
signiﬁcantly higher in the controls than in the three
patient groups, was entered as a covariate in the
analysis (F3,180=14.05, p<0.0001). As can be seen in
Fig. 1, one of the schizophrenic patients had an outly-
ing high score on the WMS. Repeating the above
analyses excluding this patient made no diﬀerence to
the ﬁndings.
Concerning the individual WMS subtests, signiﬁ-
cant diﬀerences were found on verbal memory
(F3,183=22.44, p<0.0001) and working memory
(F3,183=20.33, p<0.0001), with the controls showing
higher scores than each of the three patient groups
(Table 2). On visual memory, a marginally signiﬁcant
eﬀect (F3,183=2.61, p=0.05) was due to a signiﬁcant
diﬀerence only between the controls and the schizo-
phrenic patients (p=0.04).
Executive function
All three patient groups showed statistically signiﬁ-
cant lower standardized BADS proﬁle scores than the
control group (F3,183=24.79, p<0.0001) (Table 2 and
Fig. 2). There were no signiﬁcant diﬀerences between
any of the patient groups on this measure.
Table 1. Demographic and clinical data for three patient groups and healthy controls
A B C D Statistical
test
Post-hoc
comparisonHC BD SADM SZ
Sex ratio (F/M) 26/39 25/26 9/17 15/30 x2=3.66
p=0.30
Age (years) 38.20 (14.24) 41.09 (11.49) 41.78 (8.55) 38.10 (9.27) F3,183=1.12
p=0.34
Duration of illness (years) N.A. 13.36 (10.73) 17.57 (9.59) 16.82 (7.93) F2,112=2.18
p=0.12
Estimated pre-morbid IQ 102.06 (8.81) 101.20 (8.25) 102.08 (11.10) 100.39 (10.04) F3,179=0.33
p=0.80
WAIS-III IQ 103.34 (13.82) 93.14 (14.46) 91.12(14.41) 89.27 (15.89) F3,181=10.19 A>B,C,D
p<0.001
GAF score N.A. 47.06 (12.73) 49.62 (8.82) 46.28 (10.12) F2,117=0.76
p=0.47
YMRS score N.A. 22.65 (4.45) 22.28 (2.44) N.A. T74=0.38
p=0.70
PANSS-P N.A. 17.76 (5.05) 21.76 (3.65) 18.53 (5.06) F2,116=5.99 C>B,D
p=0.003
PANSS-N N.A. 8.31 (1.59) 11.16 (5.44) 21.40 (7.10) F2,116=82.13 D>B,C
p<0.001
PANSS-GP N.A. 25.78 (6.40) 28.36 (6.32) 34.26 (6.48) F2,116=20.77 D>B,C
P<0.001
HC, Healthy controls ; BD, bipolar disorder ; SADM, schizoaﬀective disorder, mania ; SZ, schizophrenia ; F, female ; M, male ;
WAIS-III, Wechsler Adult Intelligence Scale-III ; GAF, Global Assessment of Functioning ; YMRS, Young Mania Rating Scale ;
PANSS, Positive and Negative Symptom Scale : P, Positive ; N, Negative ; GP, General Psychopathology ; N.A., not applicable.
Values given as mean (standard deviation).
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Diﬀerences between the controls and patients on
the BADS standardized proﬁle score remained sig-
niﬁcant after correcting for current (i.e. WAIS-III)
IQ diﬀerences (F3,180=13.52, p<0.0001). The schizo-
phrenia patient who had an outlying high score on
the WMS composite score also had a high BADS
standardized proﬁle score. Once again, however,
repeating the analyses excluding this patient made no
diﬀerence to the pattern of results (Fig. 2).
As shown in Table 2, the control group performed
signiﬁcantly better than each of the patient groups
on three of the six BADS subtests, Rule Shift Cards,
Zoo Map and the Modiﬁed Six Elements Test. The
controls also performed signiﬁcantly better than the
Table 2. Neuropsychological performance on cognitive domains
A B C D
Statistical
test
Post-hoc
comparison
HC BD SAD SZ
(n=65) (n=51) (n=26) (n=45)
WMS composite score 39.05 (7.31) 28.55 (6.64) 30.23 (6.22) 28.07 (8.39) F3,183=26.73 A>B,C,D
p<0.001
WMS Verbal Memory 9.71 (2.16) 6.71 (2.54) 7.15 (3.07) 6.03 (2.91) F3,183=22.10 A>B,C,D
p<0.001
WMS Working Memory 9.86 (2.44) 7.07 (1.96) 7.17 (2.08) 7.12 (2.54) F3,183=20.33 A>B,C,D
p<0.001
WMS Visual Memory 9.62 (2.83) 9.04 (2.83) 8.85 (2.34) 8.07 (3.22) F3,183=2.61 A>D
p=0.05
BADS: Total 96.58 (13.11) 73.45 (19.09) 71.27 (21.27) 73.78 (19.81) F3,183=24.79 A>B,C,D
p<0.001
BADS: Rule Shift Cards Test 4 (1–4) 3 (0–4) 3 (0–4) 3 (0–4) KW3=42.26 A>B,C,D
p<0.001
BADS: Action Programme Test 4 (2–4) 4 (0–4) 4 (0–4) 3 (0–4) KW3=19.62 A>D
p<0.01
BADS: Key Search Test 3 (0–4) 1 (0–4) 1 (0–4) 1 (0–4) KW3=13.59 A>B
p<0.001
BADS: Temporal Judgement Test 2 (1–4) 2 (1–4) 2 (0–3) 2 (1–4) KW3=9.09
p=0.03
BADS: Zoo Map Test 2 (0–4) 1 (0–4) 1 (0–3) 1 (0–4) KW3=32.23 A>B,C,D
p<0.001
BADS: Modiﬁed Six Elements Test 4 (1–4) 3 (0–4) 2 (0–4) 3 (0–4) KW3=27.84 A>B,C,D
p<0.001
HC, Healthy controls ; BD, bipolar disorder ; SADM, schizoaﬀective disorder, mania ; SZ, schizophrenia ; WMS, Wechsler
Memory Scale ; BADS, Behavioural Assessment of the Dysexecutive Syndrome ; KW, Kruskal–Wallis test.
Values given as mean (standard deviation) or median (range).
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Fig. 1. Diﬀerences in Wechsler Memory Scale (WMS) composite scores of patient groups and healthy controls (HC). BD, Bipolar
disorder ; SADM, schizoaﬀective disorder, mania ; SZ, schizophrenia. , Represents individual outliers.
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schizophrenic patients on the Action Programme Test,
and better than the bipolar patients on the Key Search
Test.
Subanalysis of bipolar non-psychotic versus
psychotic patients
There were 22 manic patients with psychotic symp-
toms and 29 without psychotic symptoms, as deﬁned
on the basis of PANSS psychotic symptom scores
(see Method). The two groups did not diﬀer statisti-
cally signiﬁcantly in sex, age or TAP-estimated IQ
(with psychotic symptoms 10 men/12 women, with-
out psychotic symptoms 15 men/14 women, x2=0.2,
p=0.66) : age with psychotic symptoms 40.38 (S.D.=
10.94) years, without psychotic symptoms 41.63
(S.D.=12.06) years (t=0.38, p=0.70) ; TAP IQ with
psychotic symptoms 99.27 (S.D.=8.47), without psy-
chotic symptoms 102.78 (S.D.=7.87 ; t=1.49, p=0.14).
No signiﬁcant diﬀerences were found between the
two groups on either of the two global neuropsycho-
logical measures (WMS composite score 28.09 v. 30.66,
t=1.38, p=0.17 ; BADS proﬁle score 69.41 v. 76.52,
t=1.33, p=0.19). There were also no diﬀerences in any
subtest scores (data not shown).
Association of demographic and clinical status
variables with neuropsychological performance
Backward linear regression models for WMS com-
posite and BADS standardized proﬁle scores were ﬁt-
ted for each of the clinical groups using the following
variables : age, gender, duration of illness, YMRS score
and PANSS-P, PANSS-N and PANSS-GP scores. In
the bipolar group, the WMS composite score was
not predicted by any of the independent variables.
However, age and PANSS-P scores were predictive of
better BADS standardized proﬁle scores in this group
(F2,44=7.78, p<0.001, adjusted R2=0.23), with younger
patients and those with lower PANSS-P scores per-
forming better.
In the schizoaﬀective group, WMS composite score
was predicted by PANSS-N and PANSS-P scores
(F2,21=6.42, p=0.007, adjusted R2=0.32). Performance
on the BADS was predicted by gender and YMRS
score at trend level (F2,21=2.73, p=0.09, adjusted
R2=0.13), with men and those with a lower YMRS
score performing better.
In the schizophrenic group, WMS composite score
was predicted by PANSS-P and PANSS-N symptom
scores (F2,39=6.03, p=0.005, adjusted R2=0.20). With
respect to executive functioning, duration of illness
was found to be the only signiﬁcant predictor
(F1,40=7.12, p=0.011, adjusted R2=0.13).
Discussion
This study found little evidence of diﬀerences in
memory and executive function among acutely ill
patients with schizophrenia, schizoaﬀective disorder
and bipolar disorder. Out of 10 tests, there was only
one signiﬁcant diﬀerence : the schizoaﬀective patients
and the bipolar patients performed better than the
schizophrenic patients on the Action Programme Test
of the BADS, which tests problem-solving skills. These
ﬁndings do not support the proposal that
schizoaﬀective disorder resembles schizophrenia, but
is distinct from aﬀective disorder, at the cognitive le-
vel. Nor do they support a continuum of increasing
cognitive impairment from bipolar disorder through
schizoaﬀective disorder to schizophrenia. The failure
to ﬁnd diﬀerences among the three patient groups did
not seem to be attributable to the presence of psychotic
symptoms in bipolar patients because bipolar patients
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Fig. 2. Diﬀerences in Behavioral Assessment of the Dysexecutive Syndrome (BADS) standardized proﬁle scores of patient
groups and healthy controls (HC). BD, Bipolar disorder ; SADM, schizoaﬀective disorder, mania ; SZ, schizophrenia.
, Represents individual outliers.
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with and without such symptoms showed a similar
level of cognitive performance.
With respect to the comparison between schizo-
phrenia and schizoaﬀective disorder, our ﬁndings
diﬀer from those of Bora et al.’s (2009) meta-analysis,
which found less cognitive impairment in schizo-
aﬀective disorder in ﬁve out of six domains of func-
tion. Two factors may be relevant here. First, the eﬀect
sizes that Bora et al. (2009) reported were all in the
small range. Second, Bora et al. (2009) also found that
the presence of negative symptoms signiﬁcantly
moderated diﬀerences in memory, executive function
and processing speed (at least in the meta-analysis of
schizophrenia versus schizoaﬀective disorder plus
psychotic aﬀective disorder, they did not examine
schizoaﬀective disorder and bipolar disorder
separately). If negative symptoms are more severe in
schizophrenia than in schizoaﬀective disorder, and it
seems plausible to assume that they are, this by itself
might account for the appearance of diﬀerences when
a large pooled sample of patients with the two dis-
orders is considered.
Our failure to ﬁnd support for an intuitive alterna-
tive hypothesis, that cognitive impairment increases
from bipolar disorder to schizoaﬀective disorder to
schizophrenia, also seems surprising. Nevertheless,
it is in line with the results of four other studies that
have compared cognitive function across all three
disorders, none of which found clear evidence for
a continuum of impairment. Thus, Evans et al. (1999)
found that overall performance on a neuropsycho-
logical test battery did not diﬀer between 154 schizo-
phrenic patients and 29 schizoaﬀective patients, but
both groups were more impaired than 27 patients
with non-psychotic mood disorder. Glahn et al. (2006)
compared performance on three working memory
tests in 15 schizophrenic patients, 15 with
schizoaﬀective disorder, and 11 and 15 with psychotic
and non-psychotic forms of bipolar disorder respect-
ively. A stepwise pattern of impairment was evident
in only one test, forward digit span, and even here the
diﬀerences among the groups did not always reach
signiﬁcance. Szoke et al. (2008) compared 48 patients
with schizophrenia, 26 with schizoaﬀective disorder,
52 with psychotic bipolar disorder and 40 with non-
psychotic bipolar disorder. They found evidence for
progressively less impairment on one measure,
number of perseverative errors on the WCST, but not
on the other test used, the TMT. Finally, Verdoux &
Liraud (2000) compared 20 patients with schizo-
phrenia, 29 with other psychotic disorders (including
schizoaﬀective disorder), 33 with bipolar disorder and
19 with major depression. The patient groups did not
diﬀer in performance on two executive tests, the
WCST and the Stroop. Nor were there any diﬀerences
among the groups on most of the seven subtests of a
memory battery ; when diﬀerences were found, these
were only between the schizophrenic patients and
those with major depression.
Perhaps most surprising of all, our ﬁndings run
counter to the prevailing view that cognitive impair-
ment in major aﬀective disorder is less marked than in
schizophrenia. This view is exempliﬁed by Buchanan
et al. (2005), who compared meta-analyses of neuro-
psychological studies in schizophrenia, bipolar dis-
order and major depression and concluded that they
diﬀered in the severity, and perhaps also the pattern,
of impairment. Studies that have directly compared
schizophrenia and major aﬀective disorder paint a
rather diﬀerent picture, however. Daban et al. (2006)
reviewed 38 studies comparing neuropsychological
test performance in groups of schizophrenic and
bipolar patients (some of which also included a
proportion of unipolar depressed patients) and noted
that ﬁndings of no diﬀerence were approximately as
frequent as those of signiﬁcant diﬀerence. This pattern
held true across several domains of cognitive function,
including sustained attention, executive function and
memory. The only exception was in studies of IQ,
where seven out of eight studies found that schizo-
phrenic patients had a signiﬁcantly lower WAIS IQ
than bipolar patients.
It is possible that the mixed ﬁndings of the studies
in Daban et al.’s (2006) review may be related to this
last ﬁnding. Thus, it is well established that patients
with schizophrenia have a lower pre-morbid IQ than
the population as a whole (Welham et al. 2009 ; Palmer
et al. 2009). By contrast, studies of bipolar patients
have found either no pre-morbid IQ disadvantage
(Gilvarry et al. 2000 ; Zammit et al. 2004) or only a small
decrement (Reichenberg et al. 2002). Because per-
formance on all speciﬁc cognitive tests is by deﬁnition
correlated with IQ, if pre-morbid IQ is not matched
across the schizophrenic and aﬀective samples, diﬀer-
ences in test performance simply due to this factor are
likely to be found.
As noted in the Introduction, another factor that
needs to be taken into account when comparing
cognitive function between schizophrenic and bipolar
patients is phase of illness. If cognitive impairment is
stable despite ﬂuctuations in clinical state in schizo-
phrenia, but improves with remission in bipolar dis-
order, diﬀerences between the two will be inﬂated if
the bipolar patients are examined in remission. Our
study, which tested all patient groups when they were
acutely ill, suggests that this factor may be important.
Additionally, the view that cognitive function ﬂuc-
tuates with clinical status in bipolar disorder may not
be as robust as commonly thought. Thus, eﬀect sizes
for cognitive impairment in euthymia have been
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found to be in the medium or large range in several
areas of cognitive function, including particularly
executive function and memory (Robinson et al. 2006).
Furthermore, in one of the very few studies that
directly compared groups of depressed, manic and
euthymic bipolar patients, Martı´nez-Ara´n et al. (2004)
found that signiﬁcant diﬀerences were scarce, and
there were no instances where the euthymic patients’
performance clearly separated from that of the manic
or depressed patients.
In summary, our ﬁndings support conclusions
reached in imaging studies by Malhi et al. (2008) and
genetic studies by Craddock et al. (2005) and Fallin
et al. (2005) that the diagnostic categories of schizo-
phrenia, schizoaﬀective disorder and bipolar disorder
are not clearly demarcated by neurobiological ﬁnd-
ings. This could be considered in line with the current
‘deconstruction’ of the concepts of bipolar disorder,
schizoaﬀective disorder and schizophrenia at the
clinical level, which suggests that many of the diﬀer-
ences between them may be better construed as di-
mensional in nature (Vieta & Phillips, 2007). Among
the limitations of the study, one is that larger group
sizes might have demonstrated more signiﬁcant
diﬀerences, especially on the subtests of the BADS.
Additionally, we only studied bipolar I patients and
no generalization can be made regarding bipolar II
patients or patients within the so-called bipolar spec-
trum. Furthermore, the study was carried out on
patients who were receiving treatment, and for obvi-
ous reasons this diﬀered across the diﬀerent groups.
Finally, our ﬁndings cannot be generalized to schi-
zoaﬀective disorder, depressive type.
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